Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug

Status Completed

Clinical Trial Summary

This study examines the impact of UV-C light disinfection as an adjunct to routine daily and discharge patient room cleaning on patient infection and colonization with hospital associated bacteria.

Patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. Total of 83 rooms.

Clinical Trial Description

Effective cleaning of the patient environment (the patient room during hospital stay) is subject to human factors and unfortunately is often inconsistent or inadequate. Patient rooms that have residual bacteria after routine environmental cleaning can act as reservoirs for multidrug-resistant organisms (MDROs) and contribute to the spread of MDROs from patient to patient. In the setting of an increased focus on Healthcare-associated Infections such as Clostridium difficile (C. difficile) and multidrug-resistant Gram negative and Gram positive organisms such as carbapenem-resistant Enterobacteriaceae (CRE), vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphlococcus aureus (MRSA), Ultra-Violet C (UV-C) light has been shown to be a safe, effective way to decrease the burden of MDROs in patient rooms. However, studies examining the effectiveness of UV-C light when used post daily and discharge patient room cleaning are lacking.

This study is a cluster, randomized, two-period cross over trial to investigate the relationship between environmental decontamination with UV-C light and transmission of VRE and other healthcare-associated bacteria. It investigates the hypothesis that UV-C in addition to daily cleaning leads to decreased patient acquisition of healthcare-associated bacteria.

This study is important to further advance hospital-based infection prevention knowledge of the impact of UV-C light for environmental cleaning.

Patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. Total of 83 rooms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02605499
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Completed
Phase	N/A
Start date	December 2015
Completion date	February 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04976829` - Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO)
Recruiting	`NCT05589727` - Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
Completed	`NCT04873557` - Copper Use as Protection Against Antimicrobial Resistance in the ICU	N/A
Completed	`NCT03843021` - Ventricular Assist Device (VAD) Infection Prevention Survey
Recruiting	`NCT04579094` - Prevalence and Risk Factors for the Carriage of Bacteria and Clostridioid in Elderly Dependent Persons
Recruiting	`NCT04192435` - Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery	Phase 4
Recruiting	`NCT06216080` - Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients
Enrolling by invitation	`NCT03924934` - Community-associated Highly-Resistant Enterobacterales
Recruiting	`NCT06379139` - Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients
Recruiting	`NCT06155747` - Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
Completed	`NCT03349268` - Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection	N/A
Completed	`NCT04053257` - Effect of Video Camera Monitoring Feedback on Hand Hygiene Compliance and Infections in NICU	N/A
Not yet recruiting	`NCT03189043` - Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections	Phase 2
Completed	`NCT05797818` - Red Light Photobiomodulation and Topical Disinfectants	Phase 1/Phase 2
Terminated	`NCT03361085` - Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)	N/A
Completed	`NCT04770597` - Monitors to Improve Indoor Carbon Dioxide (CO2) Concentrations in the Hospital	N/A
Recruiting	`NCT05612672` - Evaluation of GeoHAI Implementation	N/A
Completed	`NCT04676581` - Risk Benefit Ratio of Hirudotherapy: Retrospective Single-center Study of 37 Cases Over a Period of 9 Years
Recruiting	`NCT05979545` - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics	Phase 4
Active, not recruiting	`NCT04312243` - NO Prevention of COVID-19 for Healthcare Providers	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO) — UVCLEAR-MDRO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms